25
Participants
Start Date
December 16, 2020
Primary Completion Date
December 19, 2023
Study Completion Date
December 19, 2023
M5049
Participants will receive low oral dose of M5049, twice daily in Part A.
M5049
Participants will receive ascending oral dose of M5049, twice daily in Part A.
M5049
Participants will receive high oral dose of M5049, twice daily in Part B.
Placebo
Participants will receive placebo matched to M5049.
Medical center Medconsult Pleven OOD, Pleven
Medical Center-1-Sevlievo EOOD, Sevlievo
Military Medical Academy - MHAT - Sofia, Sofia
"UMHAT Sv. Ivan Rilski, EAD", Sofia
SocraTec R&D GmbH, Erfurt
Fraunhofer ITMP (Fraunhofer Institute for Translational Medicine and Pharmacology), Frankfurt
ARENSIA Exploratory Medicine Phase I Unit, Clinical Republican Hospital, Chisinau
PHI University Clinic of Rheumatology Skopje, Skopje
Hospital Universitario Nuestra Señora de Valme, Seville
Hospital Universitario Virgen del Rocio, Seville
Hospital Universitario Rio Hortega - Servicio de Medicina Interna, Valladolid
"Medical Center of Limited Liability Company Harmoniya krasy, Department of clinical trials", Kyiv
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
INDUSTRY